Last reviewed · How we verify
Niaspan (Nicotinic Acid)
At a glance
| Generic name | Nicotinic Acid |
|---|---|
| Also known as | Tredaptive, Niacin, Niacin 500 (Jamp Pharma) NPN 00557412, niacin |
| Sponsor | Medpointe Pharm Hlc |
| Drug class | Non-Standardized Food Allergenic Extract [EPC] |
| Target | Hydroxycarboxylic acid receptor 2 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1957 |
Approved indications
- Methylation support
Common side effects
- Flushing
- Diarrhea
- Nausea
- Vomiting
- Increased cough
- Pruritus
- Rash
- Dizziness
- Tachycardia
- Palpitations
- Shortness of breath
- Sweating
Serious adverse events
- Syncope
- Rhabdomyolysis
- Diabetes mellitus
Drug interactions
- pravastatin
- simvastatin
Key clinical trials
- Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma (PHASE1)
- Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate (NA)
- Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia (PHASE1)
- Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia (EARLY_PHASE1)
- Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma (PHASE1)
- Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment (PHASE4)
- MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib (PHASE3)
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Niaspan CI brief — competitive landscape report
- Niaspan updates RSS · CI watch RSS
- Medpointe Pharm Hlc portfolio CI